COMMUNIQUÉS West-GlobeNewswire

Vystar Contracts Rubber Expert Ranjit Matthan for Deproteinized Dry Rubber and Latex R&D
03/06/2019
WORCESTER, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- Vystar Corp . (OTC Pink: VYST) extended and expanded its multi-year contract with Ranjit K. Matthan, Ph.D., an internationally renowned latex and rubber science expert [...]
Aptose Announces Closing of Public Offering of Common Shares
03/06/2019
SAN DIEGO and TORONTO, June 03, 2019 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), today announced the closing of its previously announced underwritten public offering [...]
Progenics Announces Updated Survival Data for AZEDRA® (iobenguane I 131) in Advanced Pheochromocytoma and Paraganglioma
03/06/2019
- Long-Term Follow Up Data from Pivotal Study Presented at ASCO - - Patients Treated with AZEDRA Show Overall Survival of 73.1% at Two Years and 44.2% at Four Years - NEW YORK, June 03, 2019 (GLOBE NEWSWIRE) -- [...]
Aeglea BioTherapeutics Doses First Patient in Pivotal Phase 3 PEACE Trial of Pegzilarginase in Arginase 1 Deficiency
03/06/2019
Topline Data from PEACE Anticipated in First Quarter of 2021 New Data from ARG1-D Phase 1/2 Extension Study Expected in September 2019 AUSTIN, Texas, June 03, 2019 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. ( [...]
Align Technology Awards Funding to Universities Worldwide for Advancing Orthodontic and Dental Research
03/06/2019
$250,000 in Research Grants Awarded as Part of its Ongoing Annual Research Awards Program SAN JOSE, Calif., June 03, 2019 (GLOBE NEWSWIRE) -- Align Technology, Inc. (Nasdaq: ALGN) today announced the award of ten [...]
SELLAS Announces Immune Response Data in Triple Negative Breast Cancer Patients from Phase 2b Study of Nelipepimut-S (NPS) Plus Trastuzumab Presented at ASCO 2019
03/06/2019
NPS-Specific Cytotoxic T-Lymphocyte Mean Frequencies Increased by 2.86-fold Compared to Baseline at 30 months Notable Correlation Between Progressive Increase of NPS-Specific Cytotoxic T-Lymphocyte in NPS Plus [...]
Advantis Corporation Takes Major Step Toward OTC QB
03/06/2019
NEWPORT BEACH, CA, June 03, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - ADVANTIS CORPORATION (OTC PINK: ADVT) announced that is has begun the necessary audit process in order to up-list the stock to the OTC QB. Advantis [...]
Merus to Present at the Jefferies 2019 Healthcare Conference
03/06/2019
UTRECHT, Netherlands, June 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length human [...]
Matinas BioPharma to Present at the 9th Annual LD Micro Invitational
03/06/2019
Presentation with live audio webcast Tuesday, June 4th at 1:20 PM PT BEDMINSTER, N.J., June 03, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, [...]
VBL Final Phase 1/2 Study Results Presented at ASCO Demonstrate VB-111 Dose Dependent Increase in Overall Survival and 58% CA-125 Response Rate in Platinum-Resistant Ovarian Cancer
03/06/2019
VB-111 demonstrated a statistically significant increase in overall survival at therapeutic vs. low dose (498 days vs. 172.5 days, p=0.03) CA-125 response (GCIG) was reported in 58% of evaluable patients and was [...]
Radiographic Analysis of VB-111 Phase 2 and 3 Clinical Trials in Recurrent Glioblastoma Shows Survival Benefit Associated with Objective Responses and Distinct Signature of VB-111 Activity
03/06/2019
TEL AVIV, Israel, June 03, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), today announced that MRI data from VB-111 Phase 2 and Phase 3 studies in recurrent GBM (rGBM), presented yesterday at the 2019 [...]
Scapa Healthcare Opens New Medical Device Manufacturing Facility in Knoxville, TN
03/06/2019
Opening Ribbon Cutting Ceremony Held June 3rd, 2019 WINDSOR, Conn., June 03, 2019 (GLOBE NEWSWIRE) -- Scapa Healthcare , the trusted strategic partner of choice to the world’s leading companies in advanced wound care, [...]
Imagin Medical to Report Second Fiscal Quarter 2019 Financial Results on June 11, 2019 – Conference Call to Follow
03/06/2019
VANCOUVER, British Columbia and BOSTON, June 03, 2019 (GLOBE NEWSWIRE) -- Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (“Imagin” or the “Company”), an emerging leader in the [...]
Kaleido Biosciences to Present at the Goldman Sachs 40th Annual Global Healthcare Conference
03/06/2019
LEXINGTON, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to leveraging the potential of the [...]
TransMedics Announces the Second FDA PMA Approval for its OCS Lung System, Allowing Access to a Larger Pool of Donor Lungs that are Currently Seldomly Utilized for Transplantation Due to Limitations of Cold Storage
03/06/2019
ANDOVER, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- TransMedics Group, Inc. (“TransMedics”) (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, [...]
Cellworks myCare™ Clinical Trial Transforms NGS Data into Personalized Cancer Therapy Actions
03/06/2019
New Trial Biosimulates Efficacy of Cancer Therapies Using Molecular Genetic Aberration Data CHICAGO, June 03, 2019 (GLOBE NEWSWIRE) -- 2019 ASCO Annual Meeting – Cellworks Group, Inc., a leader in Precision Medicine and [...]
Forty Seven, Inc. Announces Updated Initial Data from Phase 1b Clinical Trial of 5F9 in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia
03/06/2019
-- 5F9 Well Tolerated with Clinical Activity as Monotherapy and in Combination with Azacitidine -- -- CR Rate of 55% and ORR of 100% Observed in Patients with Higher-Risk MDS -- -- CR/CRi Rate of 50% and ORR of 64% [...]
Cue Biopharma to Present Corporate Overview & Clinical Strategy for CUE-101 at Jefferies 2019 Healthcare Conference
03/06/2019
CAMBRIDGE, Mass., June 03, 2019 (GLOBE NEWSWIRE) -- Cue Biopharma , Inc., (NASDAQ: CUE) an innovative clinical stage immunotherapy company developing a novel, proprietary class of biologics engineered to selectively [...]
Afrezza® (insulin human) Inhalation Powder Approved in Brazil
03/06/2019
Afrezza® is the only orally inhaled ultra rapid-acting mealtime insulin approved by ANVISA in Brazil. The innovative delivery system reduces injections while improving glycemic control in adult patients with diabetes [...]

Pages